Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03412643
Title Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)
Acronym FB-12
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors NSABP Foundation Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.